Stipple Bio

About Stipple Bio

Stipple Bio is a company focused on revolutionizing targeted oncology with epitope level precision to develop life-changing medicines for people with cancer. Their approach involves revealing tumor-specific epitopes by mapping subtle molecular points, akin to stippling or pointillism in art, to identify targets often invisible to traditional methods.

Products & Services

Platform:A platform likely focused on precision-driven oncology for discovering tumor-specific epitopes.

Pipeline:A pipeline of potential oncology therapies or products under development.

Specialties

Targeted Oncology Epitope Level Precision Tumor-Specific Epitope Discovery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2026-04-06 FD: 2026-04-06	7 investors

Series A Latest

2026-04-06

$100.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Aaron Ring

Associate Professor

A

Aashish Manglik

Associate Professor

J

Jeff Landau

Chief Executive Officer

LinkedIn (Pro only)

M

Michelle Zhang

Chief Scientific Officer

A

Andrew "Andi" Lake

Vice President of Translational Biology

V

Vineeta Agarwala

General Partner, Andreessen Horowitz (a16z)

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

Stipple Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised